Literature DB >> 9069609

Alternatives to the QALY measure for economic evaluations.

A Gafni1.   

Abstract

Economic analyses (i.e., analyses that are concerned primarily with questions of resource allocation) are becoming more common in health care in general and care of cancer patients in particular. The most commonly used measure for the valuation of outcome in such analyses is the QALY (quality-adjusted life-years), which combines qualitative (i.e., quality of life) and quantitative (i.e., survival) aspects of the outcome into one dimension. Using economics (i.e., the discipline) as the mode of thinking to help solve problems of resource allocation in health, this paper describes a framework to evaluate the appropriateness of use of a measure of outcome in the context of an economic evaluation. This framework will be used to critically appraise the use of the QALY measure and of two alternative measures, HYE (healthy years equivalent) and WTP (willingness to pay), in economic evaluations of health care interventions. The paper also describes a practical tool that can be used to measure individuals' WTP in the context of public decision making. This tool involves modifying the decision board, a tool develop (originally in the cancer area) to help clinicians present information to patients. The intent is to show that the use of a theoretically superior measure of outcome need not always be empirically restrictive.

Entities:  

Mesh:

Year:  1997        PMID: 9069609     DOI: 10.1007/bf01262566

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  19 in total

Review 1.  Implications of basing health-care resource allocations on cost-utility analysis in the presence of externalities.

Authors:  R J Labelle; J E Hurley
Journal:  J Health Econ       Date:  1992-10       Impact factor: 3.883

2.  Economics, health and health economics: HYEs (healthy-years equivalent) versus QALYs (quality-adjusted live-year)

Authors:  A Gafni; S Birch; A Mehrez
Journal:  J Health Econ       Date:  1993-10       Impact factor: 3.883

3.  Willingness-to-pay as a measure of benefits. Relevant questions in the context of public decisionmaking about health care programs.

Authors:  A Gafni
Journal:  Med Care       Date:  1991-12       Impact factor: 2.983

Review 4.  When do the "dollars" make sense? Toward a conceptual framework for contingent valuation studies in health care.

Authors:  B O'Brien; A Gafni
Journal:  Med Decis Making       Date:  1996 Jul-Sep       Impact factor: 2.583

Review 5.  Proper preference-based outcome measures in economic evaluations of pharmaceutical interventions.

Authors:  A Gafni
Journal:  Med Care       Date:  1996-12       Impact factor: 2.983

6.  Quality-adjusted life years, utility theory, and healthy-years equivalents.

Authors:  A Mehrez; A Gafni
Journal:  Med Decis Making       Date:  1989 Apr-Jun       Impact factor: 2.583

7.  Preferences for outcomes in economic evaluation: an economic approach to addressing economic problems.

Authors:  A Gafni; S Birch
Journal:  Soc Sci Med       Date:  1995-03       Impact factor: 4.634

8.  The ranking properties of healthy-years equivalents and quality-adjusted life-years under certainty and uncertainty.

Authors:  M Johannesson
Journal:  Int J Technol Assess Health Care       Date:  1995       Impact factor: 2.188

Review 9.  Methods for assessing relative importance in preference based outcome measures.

Authors:  R M Kaplan; D Feeny; D A Revicki
Journal:  Qual Life Res       Date:  1993-12       Impact factor: 4.147

10.  Design and validation of a bedside decision instrument to elicit a patient's preference concerning allogenic bone marrow transplantation in chronic myeloid leukemia.

Authors:  C Sebban; G Browman; A Gafni; G Norman; M Levine; D Assouline; D Fiere
Journal:  Am J Hematol       Date:  1995-04       Impact factor: 10.047

View more
  7 in total

1.  Health profile preferences of hepatitis C patients.

Authors:  J R Treadwell; D Kearney; M Davila
Journal:  Dig Dis Sci       Date:  2000-02       Impact factor: 3.199

2.  Dalteparin versus warfarin for the prevention of recurrent venous thromboembolic events in cancer patients: a pharmacoeconomic analysis.

Authors:  George Dranitsaris; Mark Vincent; Mark Crowther
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

3.  Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria.

Authors:  George Dranitsaris; Lesley G Shane; Jean-Philippe Galanaud; Gunar Stemer; Philippe Debourdeau; Seth Woodruff
Journal:  Support Care Cancer       Date:  2017-02-15       Impact factor: 3.603

Review 4.  The impact of economic evaluation on quality management in spine surgery.

Authors:  Norbert Boos
Journal:  Eur Spine J       Date:  2009-04-01       Impact factor: 3.134

5.  Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective.

Authors:  George Dranitsaris; Bo Yu; Jennifer King; Satyin Kaura; Adams Zhang
Journal:  Clinicoecon Outcomes Res       Date:  2015-05-12

6.  Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis.

Authors:  George Dranitsaris; Lesley G Shane; Mark Crowther; Guillaume Feugere; Seth Woodruff
Journal:  Clinicoecon Outcomes Res       Date:  2017-01-10

7.  Prevalence of Missing Values and Protest Zeros in Contingent Valuation in Dental Medicine.

Authors:  Pedram Sendi; Arta Ramadani; Michael M Bornstein
Journal:  Int J Environ Res Public Health       Date:  2021-07-06       Impact factor: 3.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.